I'm LongbridgeAI, I can summarize articles.NewcelX (NCEL) announced the publication of a peer-reviewed study in Stem Cell Reports highlighting its AstroRx therapy for multiple sclerosis. The study demonstrated that AstroRx enhances myelin debris clearance and supports immune regulation, validating NewcelX's stem cell platform. This external validation underscores the potential to broaden indications while the company advances its lead diabetes candidate, NCEL-101.
An update from NewcelX ( (NCEL) ) is now available.
On June 15, 2026, Switzerland-based NewcelX announced publication of a peer-reviewed study in Stem Cell Reports highlighting AstroRx, its clinical-grade hESC-derived astrocyte therapy, as a promising treatment approach for multiple sclerosis and other chronic demyelinating diseases. The data, generated with academic collaborators, showed AstroRx enhanced myelin debris clearance, supported immune regulation, and accelerated oligodendrocyte progenitor differentiation, bolstering external validation of NewcelX’s stem cell platform and underscoring its potential to broaden indications while it advances lead diabetes candidate NCEL-101.
More about NewcelX
NewcelX Ltd. is a clinical-stage regenerative medicine and biopharmaceutical company focused on developing transformative stem-cell-derived therapies for type 1 diabetes. Built on a human pluripotent stem cell platform, its lead program NCEL-101 aims to restore functional insulin production via scalable, off-the-shelf cell replacement solutions for critical unmet medical needs.
Average Trading Volume: 52,431
Technical Sentiment Signal: Sell
Current Market Cap: $17.26M
For an in-depth examination of NCEL stock, go to TipRanks’ Overview page.